GTF2B Polyclonal antibody

GTF2B Polyclonal Antibody for IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IP, ELISA

Conjugate

Unconjugated

Cat no : 16467-1-AP

Synonyms

GTF2B, S300 II, TF2B, TFIIB



Tested Applications

Positive WB detected inK-562 cells, HepG2 cells, HeLa cells, MCF-7 cells
Positive IP detected inK-562 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Published Applications

WBSee 2 publications below

Product Information

16467-1-AP targets GTF2B in WB, IP, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen GTF2B fusion protein Ag9547
Full Name general transcription factor IIB
Calculated Molecular Weight 316 aa, 35 kDa
Observed Molecular Weight 30-35 kDa
GenBank Accession NumberBC020597
Gene Symbol GTF2B
Gene ID (NCBI) 2959
RRIDAB_2878263
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Protocols

Product Specific Protocols
WB protocol for GTF2B antibody 16467-1-APDownload protocol
IP protocol for GTF2B antibody 16467-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

PLoS Biol

A novel TOX3-WDR5-ABCG2 signaling axis regulates the progression of colorectal cancer by accelerating stem-like traits and chemoresistance

Authors - Jiaojiao Hao

Am J Cancer Res

PMID: 28123844

Authors - Jiaojiao Hao
humanWB

J Exp Clin Cancer Res

Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.

Authors - Jiaojiao Hao